Hengrui Pharma Licenses HRS-1596 To Novo For Up To $2.6B

Hengrui Pharma granted Novo Nordisk exclusive rights (ex-China regions) to develop and commercialize HRS-1596, with deal value up to $2.6B including a $300M upfront payment. Closing is subject to HSR clearance and other conditions, expected in Q4 2026.Material DetailsContext by AI AnalystThis is an…